Related Experiment Video

Updated: Jul 31, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Arterial wall rather than platelets is responsible for diminished thrombogenicity during isradipine therapy

H Sinzinger1, A Keiler, J O'Grady

  • 1Wilhelm Auerswald-Atherosclerosis Research Group (ASF) Vienna, Austria.

Journal of Cardiovascular Pharmacology
|March 1, 1995
PubMed

Insights

Isradipine reduces blood clot formation by affecting the vessel wall, not platelets, in de-endothelialized arteries. This calcium channel blocker demonstrates vessel-specific antithrombotic properties.

Area of Science:

  • Cardiovascular Pharmacology
  • Hemostasis and Thrombosis
  • Vascular Biology

Background:

  • Calcium channel blockers, like isradipine, are used to treat cardiovascular conditions.
  • The precise mechanism by which isradipine reduces thrombogenicity, particularly its target (vessel wall vs. platelets), remains unclear after endothelium removal.

Purpose of the Study:

  • To determine whether the vessel wall or platelets are primarily responsible for the antithrombotic effects of isradipine.
  • To investigate the impact of isradipine on platelet adhesion, aggregation, and prostaglandin I2 (PGI2) formation in a de-endothelialized rabbit model.

Main Methods:

  • A cross-perfusion model using de-endothelialized rabbit aorta and iliac artery segments.
  • Treatment of donor and/or receiver rabbits with isradipine or acetylsalicylic acid (ASA).
  • Quantification of platelet deposition, aggregation, and PGI2 formation using morphometry and radiolabeled platelets.

Main Results:

  • Isradipine pretreatment of receiver rabbits significantly decreased platelet adhesion and aggregation, irrespective of donor treatment.
  • Concomitant ASA and isradipine treatment of donor animals showed no significant effect.
  • Treatment of receiver animals with ASA and isradipine enhanced thrombogenicity.

Conclusions:

  • The antithrombotic effect of isradipine in de-endothelialized vessels is primarily mediated by the vessel wall, not platelets.
  • Isradipine exhibits vessel-specific antithrombotic properties, suggesting a direct effect on the vascular endothelium or smooth muscle.
  • Further research is warranted to elucidate the specific molecular mechanisms involved.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...